From a global, biologicalperspective this in-fighting over alleged medical and religious ethics is in fact nothing less than an all out affront to environmental sustainability.
The bottom line is that for the time being, from a regulatory perspective each biosimilar version of an approved biological product will be regarded as, in effect, a completely new and distinct drug.
The Stanford University professor of biological sciences devotes a large amount of her time to taking a business perspective on land and water as a type of natural capital.